Binimetinib in phase 3 for for the treatment of metastatic or unresectable cutaneous melanoma with NRAS mutations and in combination with LGX-818 in adult patients with BRAF V600 « New Drug Approvals:
'via Blog this'
Tracks information on drugs on worldwide basis by Dr Anthony Melvin Crasto, helping millions with websites, 9 million hits on google, 2.5 lakh connections worldwide, P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
Subscribe to:
Post Comments (Atom)
Nice Article! Thanks for sharing the useful content.
ReplyDeleteTelecom shares
GlaxoSmithKline Pharma Ltd
JSW Steel Limited
Jubilant Industries Ltd